Full Length Research Paper

Molecular study on extended spectrum β-lactamase-producing Gram negative bacteria isolated from Ahmadi Hospital in Kuwait

Eshaq A. Mohmid1*, El-Sayed A. El-Sayed2 and Mahmoud F. Abdel El-Haliem2

1Department of Microbiology, Medical Laboratory, Ahmadi Hospital, Kuwait Oil Company, Ahmadi, Kuwait.
2Department of Botany, Faculty of Science, Zagazig University, Zagazig, Egypt.

Accepted 26 July, 2013

During the period from November 2009 to April 2010, 84 out of 560 extended spectrum β-lactamase (ESBL) producing negative bacteria were isolated from patients in different departments of the Ahmadi Hospital in Kuwait. The isolates were collected from urine catheter, wound, sputum, blood and other different samples. The ESBL infection rate in the in-patients was 62% and part of them (19%) were in the intensive care unit. All the isolated bacteria were identified and tested for antimicrobial susceptibility using an automated system (VITEK 2) and different antibiotic discs (15) by standard disc diffusion. The number of the recorded isolated multi-resistant Gram's negative bacteria was 54 isolates of Escherichia coli, 18 of Klebsiella pneumoniae, 11 of Pseudomonas aeruginosa, six of Proteus mirabilis, five of Enterobacter cloacae, four of Acinetobacter baumanii and one of Enterobacter aerogenes. They were resistant to the third generation of cephalosporins; Ceftazidime, Cefotaxime and Ceftriaxone. Meropenam (MEM) was the highest effective antibiotic against all the isolated bacteria (86%). The production of the ESBL was detected by phenotypic methods using E-test (96.4%), double disk synergy test (95%) and VITEK 2 (84.5%) in all multi-resistant isolates except A. baumanii and P. aeruginosa. All ESBL producing isolates were extracted and subjected to PCR using blaSHV, blaCTX-M and blaTEM primers. The bla-CTX-M (63.1%) was the most predominant ESBL gene that was produced in abundance by 42 isolates of E. coli. The most predominant ESBL isolates producing bla-TEM, bla-CTX-M and bla-SHV genes were successfully identified by 16S rDNA. The conjugation assay between E. coli HB101 and the most predominant ESBL producing E. coli showed that the bla-CTX-M gene was able to be transferrable suggesting that they were plasmid mediated.

Key words: Extended spectrum β-lactamase (ESBL), VITEK 2, E-Test, DDST, polymeric chain reaction (PCR), 16S rDNA.

INTRODUCTION

Extended spectrum of β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme producing organisms are associated with a higher morbi-
dity and mortality with greater fiscal burden. Coupled with increasing prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, these enzymes represent a clear and present danger to public health (Dhillon and Clark, 2011). The introduction of the third-generation of cephalosporins into clinical practice in the early 1980s is heralded as a major breakthrough in the fight against β-lactamase-mediated bacterial resistance to antibiotics.

These cephalosporins have been developed in response to the increased prevalence of β-lactamases in certain organisms (for example, ampicillin hydrolyzing TEM-1 and SHV-1 β-lactamases in E. coli and K. pneumoniae). The third generation of cephalosporins against most β-lactamase-producing organisms has major advantages of lessened nephrotoxic effects compared to aminoglycosides and polymyxins. The first report of plasmid-encoded β-lactamases capable of hydrolyzing the extended-spectrum cephalosporins, SHV-2, was published from a strain of K. ozaraneae (Knothe et al., 1983). Among Enterobacteriaceae, extended spectrum beta lactamases (ESBLs) have been found mainly in Klebsiella spp. and E. coli, but have been also reported in another genera, such as Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Salmonella, Serratia and Pseudomonas spp. (Arlet and Philippou, 1991; Ivanova et al., 2008). Thereafter, the number of ESBL variants occurring through amino acid mutations has progressively increased while demonstrating geographic variations (Winokur et al., 2001).

SHV-types of ESBLs are mostly derivatives of a non-ESBL SHV-1 and quickly invaded several continents (Bradford, 2001; Paterson et al., 2003). The majority of plasmid-mediated beta-lactamases, namely, TEM-1 or less frequently, TEM-2 are broad-spectrum beta-lactamases which do not hydrolyze oxyimino-cephalosporins or aztreonam. The (CTX-M) family, first described in 1992, is known to be the most dominant non-TEM, non-SHV ESBL among Enterobacteriaceae and it was recognized as a rapidly growing family of ESBLs that prefer to hydrolyze cefotaxime rather than ceftazidime (Bauernfeind et al., 1992; Bonnet, 2004). Several researchers used genotypic methods for the identification of the specific gene responsible for the production of the ESBLs, which have the additional ability to detect low-level resistance; that is, it can be missed by phenotypic methods (Woodford and Sundsfjord, 2005). Furthermore, molecular assays also have the potential to be done directly on clinical specimens without culturing the bacteria, with subsequent reduction of detection time (Tenover, 2007). Olsen and Woese (1993) showed that the 16S ribosomal ribonucleic acid (16S rRNA) gene, since the discovery of polymeric chain reaction (PCR) and deoxyribonucleic acid (DNA), was highly conserved within and among species of the same genus in compar-

ring the gene sequences of the bacterial species. Hence, it can be used as the new gold standard for identification of bacteria to the species level of bacterial strains that have posed problems for the accurate identification of such isolates.

The genes that encode ESBLs were frequently found on the same plasmids as genes that encode resistance to aminoglycosides and sulfonamides. Many bacterial species possess changes that confer high-level resistance to quinolones. As a result, ESBL-producing bacterial species in hospitals and intensive care units (ICU) are commonly multidrug resistant, which possess a particular challenge for the treatment of nosocomial infections, especially in critically ill patients. Inappropriate empiric antimicrobial treatment for nosocomial or community-acquired infections has been reported to contribute to significantly greater mortality rates in the ICU, and inadequate antimicrobial treatment of infection was the most important independent determinant of hospital mortality (Kollef et al., 1999). ESBLs are increasingly spreading among Enterobacteriaceae (clinical isolates) throughout the world due mostly to their presence on highly conjugative plasmid. Surveys that are done in Canada, Greece, United Kingdom and Italy showed an association between the CTX-M type of ESBL and resistance to other antimicrobial agents (Bonnet, 2004). This is explained by a number of findings showing that bla-CTX-M genes are commonly found on large plasmids that often carry other genes conferring resistance to other antimicrobial agents including aminoglycosides, fluoroquinolones, chloramphenicol, tetracyclins and others; particularly, bla-OXA-1, bla-TEM-1 (Leflon-Guibout et al., 2004; Bratu et al., 2005).

The aim of this work was to determine the prevalence of ESBL producing members of the Gram negative isolates which are isolated from samples collected from different departments at the Ahmadi Hospital in Kuwait by means of phenotypic and genotypic methods and also, characterize the genetic basis of ESBL producing isolates and compare them with the universal isolates of the gene bank.

MATERIALS AND METHODS

Bacterial isolates and sample collection

Totally, 560 clinical significant bacterial strains belonging to the family Enterobacteriaceae were isolated from patients seen and treated at the Ahmadi Hospital in Kuwait from November 2009 to April 2010. Isolates found to be resistant or with decreased susceptibility to any of the third generation of cephalosporins such as ceftazidime, cefotaxime or ceftriaxone were selected for ESBL testing (Duttary and Mehta, 2005; Paterson and Bonomo, 2005). The samples were collected from different departments and sent to the microbiology laboratory. They were (465) urine, (17) sputum, (23) catheter, (11) blood, (20) wound and (24) different samples.
The selected isolates were reviewed and recorded for the work of the study; including patient file number, diagnosis, age, sex, type of sample, location and type of infected organism.

**Identification of gram negative bacteria**

The samples were cultured on blood and MacConkey agar media (OXOID). The plates were incubated at 37°C for 24 h, and the Gram negative bacterial colonies were selected for identification and antimicrobial susceptibility testing by VITEK 2 (BioMerieux, Marcy L’Etoile, France) using ID-GNI and AST-GN27 cards according to the manufacturer’s instruction (NCCLS, 1999). Then, the results were interpreted by using software version VTK2-R 4.0.1, an advanced expert system (AES) (Livermore, 1995; Canton et al., 2001; Sanders et al., 2001), E. coli (ATCC 25922) and P. aeruginosa (ATCC 27853) were used for negative quality control in agar medium (Oxoid Ltd., 1993; Merk et al., 2007). All the isolated resistant gram negative bacteria that are resistant to the third generation cephalosporins is selected for ESBL detection and confirmation (CLSI, 2005).

**Criterion for selection of ESBL producing strains**

Routine disc diffusion susceptibility test of the isolates was performed by standard disk diffusion; Bauer-Kirby method (Bauer et al., 1968). All the isolates with the control strains were inoculated according to McFarland standards (McFarland, 1907; Farmer et al., 2007) and streaked on Mueller Hinton agar medium (Oxoid Ltd., Basingstoke, UK) using sterile cotton swabs. Then, 15 different antibiotic discs (MAST GROUP Ltd, UK), belonging to 8 groups of β- and non β-lactam agents, were added onto the plates and incubated at 37°C for 24 h. The activity of each antibiotic disc was determined by measuring the antibiotic zone diameter (NCCLS, 2003). Following the CLSI criteria; any resistant with one of the third generation cephalosporins is selected for ESBL detection and confirmation (CLSI, 2005).

**ESBL phenotypic tests**

All the isolated resistant gram negative bacteria that are resistant to the third generation cephalosporins were tested by VITEK 2, E-Test (AB Biodisk, Sweden) and double disc synergy test (DDST) methods. VITEK2 is based on the detection of the inhibitory effect of clavulanic acid on ESBLs in the presence of either cefotaxime or ceftazidime. E-test strips of cefotaxime/cefotaxime + clavulanic acid (CT/CTL) and ceftazidime/ceftazidime + clavulanic acid (TZ/TZL) are designed to confirm the presence of clavulanic acid that is able to inhibit ESBL enzymes in E. coli, K. pneumoniae, K. oxytoca and other relevant species (Cormican et al., 1996).

DDST is used to reconfirm the strains that are ESBL positive tested by E-test and VITEK 2 and employed three discs, ceftazidime (30 µg), cefotaxime (30 µg) and amoxicillin with clavulanic acid (30 µg) from Oxoid. The discs were placed with their centers at the recommended distance (25 to 30 mm) apart from each other on the plate. When the inhibition zone of ceftazidime or cefotaxime in combination singly with clavulanic acid is enhanced (zone diameter ≥ 5), it confirms an ESBL producing organism as recommended by the NCCLS (2000).

**ESBL molecular tests**

The ESBL isolates were tested in vitro as follows:

**Extraction of ESBLs**

One loopful of overnight growth ESBL isolates with the positive control strains was inoculated into 1.0 ml sterile distilled water. The bacterial suspension was emulsified and boiled for 10 min at 100°C and then kept for 5 min on ice. The emulsified suspension was centrifuged for 10 min at 12000 rpm and 300 to 400 ul from the supernatant was stored at -20°C (Lou et al., 1993; Merk et al., 2006).

**Amplification and sequencing of ESBL genes**

PCR analysis in vitro was performed on all isolates with the positive control strains containing specific primers to confirm the presence of ESBL. The ESBL coding regions were amplified using the primers listed in Table 1 and a cell suspension as template containing 2.5 ul buffer, 2.0 ul MgCl2 (Promega, Ltd, UK), 0.5 ul dNTP, 0.25 ul Taq DNA polymerase (Promega, Ltd, UK), 1.0 ul forward and retained primers, 2.0 ul DMSO (only for blaSHV primer), 2.0 ul extracted DNA and sterile water for the remaining 25.0 ul (Dashti et al., 2009). The PCR products were analyzed by agarose gel electrophoresis using 1.5% (wt/vol) in a programmable PCR master cycler gradient (Eppendorf, Germany) following the technique described by Tenover et al. (1995) and photographed using a gel documentation system (UVP Company, Upland, CA, USA). E. coli strain ATCC 25922 was used as a negative control in all PCR assays. The positive control for SHV was K. pneumoniae, whilst the positive control for TEM and CTX-M was E. coli ATCC 25922 (Dashti et al., 2010). The blaTEM and blaCTX-M PCR products were purified using the NucleoSpin Extract II (Macherey-Nagel, Duren, Germany) and sequenced using the ABI13100 DNA sequencing system (Applied Biosystem, Foster City, CA, USA). The resulting DNA sequences were compared with ESBL producing gram negative bacteria in the gene bank using BLAST at the website (http://www.ncbi.nlm.nih.gov/blas).

**Identification by 16SrDNA**

Total DNA was extracted from the most predominant ESBL producing isolates and amplified using 16SrRNA primers listed in Table 1. Presence and yield of specific PCR products (16S rRNA gene) were monitored by running 1% agarose gels and cleaned up by using GeneJET™ PCR purification kit (Fermentas). The amplified DNA fragments were sequenced at GATC Biotech AG (Konstanz, Germany) using ABI 3730xl DNA sequencing system and the 16S rDNA sequences were analyzed by using the basic local alignment search tool (BLAST) program (http://www.ncbi.nih.gov/BLAST).

**Conjugation assay**

The recipient cell in this experiment was E. coli HB101 (Maniatis et al., 1982) and the donor cell was E. coli No. 22 (The predominant isolated blaCTX-M producing Gram’s negative bacteria in this study). The strains that exhibited resistance to any of the tested antibiotics were examined for the ability to transfer resistance by conjugation. The recipient and donor strains in vitro were grown to mid-log phase. Equal volumes of donor and recipient cells were spread on a Mueller-Hinton plate and incubated for 24 h at 37°C. Positive and negative controls were prepared and examined. The resulting biomass was harvested, plated on Luria-Bertani agar.
plates (LB) containing streptomycin (16 mg/ml) and ceftazidime (8 mg/ml), and incubated for 24 h at 37°C (Sigma, USA). *E. coli* HB101 showed resistance to Streptomycin (recipient cell) while *E. coli* No. 22 was sensitive to Streptomycin (donor cell). However, *E. coli* No. 22 was resistant to ceftazidime while *E. coli* HB101 was sensitive to ceftazidime.

**RESULTS**

**Bacterial isolates**

During the period from November 2009 to April 2010, 99 out of 560 clinically significant bacterial strains belonging to the family Enterobacteriaceae were resistant to most of the 15 different antibiotic discs including the third generation cephalosporins. The multi-resistant isolates were collected from urine catheter, wound, sputum, blood and different samples. The ESBL infection rate in the hospitalized patients (62%) was higher than out-patients and most of them were in the intensive care unit (data are not shown).

**Identification of the bacterial isolates**

The red (lactose) and colorless (non-lactose) fermenting colonies on MacConkey agar or creamy (mucoid) colonies on blood agar were selected for gram stain, oxidase test and analyzed in VITEK 2 for bacterial identification. Gram's stained films showed gram's negative bacilli and oxidase test was negative for the lactose fermenting colonies and positive for non-lactose fermenting colonies. The number of the multi-resistant isolates was identified as *E. coli* (54 out of 358), *K. pneumoniae* (18 out of 96), *P. aeruginosa* (11 out 58), *P. mirabilis* (6 out of 17), *E. cloacae* (5 out of 18), *A. baumanii* (4 out of 9) and *E. aerogenes* (one out of 4). Most of the multi-resistant gram negative bacteria were isolated from urine samples (465 out of 560), whereas, blood samples were the lowest one (11 out of 560).

**Antimicrobial susceptibility test**

The isolated gram negative bacteria (Table 2) were resistant to the first, second and third generation of cephalosporins; CZL, CXM, CAZ, CTX and CRO. The antibiotic sensitivity of tigecycline (TGC), amikacin (AK), nitrofurantion (NI), gentamicin (GM), tazocin (PTZ), Amoxicillin / clavulanic acid (AUG) and ciprofloxacin (CIP) reached 84.8, 77.7, 42.4, 43.4, 71.7, 22.2 and 21.2%, respectively. All the multiresistant gram negative bacteria were sensitive to MEM (86.8%) except the isolates of *P. aeruginosa* and two isolates of *A. baumanii*. The antibiotic susceptibility of *E. coli* to TGC, AK, PTZ, NI, GM, AUG and CIP reached 84.8, 77.7, 42.4, 43.4, 71.7, 22.2 and 21.2%, respectively. The antibiotic susceptibility rate of *K. pneumoniae* showed 100% against TGC, 83% against PTZ, 66.6% against AK, 28% against CIP, 22% against GM, 16.5% against NI and 5.5% against AUG. MEM and AUG were the effective antibiotics against *E. coli* and *K. pneumoniae*, but not active against other gram negative
isolates. The isolates of *P. aeruginosa* were resistant to the tested antibiotics except CIP, PTZ, AK and GM, but MEM and TGC have antimicrobial activities against *E. aerogenes*.

### Phenotypic detection of ESBLs

The VITEK2 (Table 3) detected the presence of ESBL activity of the tested isolates (71%) represented by *K. pneumoniae* (100%) and *E. coli* (98%). Using DDST, the enhanced inhibition zone of the ceftazidime or cefotaxime in combination with clavulanic acid detected the presence of ESBL activity by 80 isolates (81%). The rate of ESBL detection reached 100% by *K. pneumoniae*, *P. mirabilis* and *E. aerogenes*, whilst 98% by *E. coli* and *E. cloacae*. The production of ESBL by DDST was not detected in one isolate of *E. coli* and three isolates of *E. cloacae*. On the other hand, the synergic activity of clavulanic acid combined with ceftazidime (TZ) or cefotaxime (CT) was confirmed by two different E-test strips containing ceftazidime and cefotaxime with or without clavulanic acid. The ceftazidime ESBL strips (TZ/TZL) detect the presence of ESBL activity by 80% of the tested isolates. Furthermore, the rate of the ESBL detection was 100% by *K. pneumoniae*, *P. mirabilis* and *E. aerogenes*; 98% by *E. coli*; and 20% by *E. cloacae*. The production of ESBL was not detected by one isolate of *E. coli* and four isolates of *E. cloacae*. With cefotaxime ESBL strips (CT/CTL), ESBL activity was detected by all the tested isolates (84%) represented by 100% in *K. pneumoniae*, *P. mirabilis*, *E. aerogenes*, *E. cloacae* and 98% in *E. coli*. The production of ESBL by ceftazidime ESBL strips was not detected in one isolate of *E. coli*. The production of ESBL was not recorded by all the tested *P. aeruginosa* and *A. baumanii* isolates in this study.

The analysis of the phenotypic ESBLs showed that there are differences between the VITEK 2 and both of the E-test and DDST. Out of 99 tested multiresistant isolates, 71 isolates recorded ESBL production by VITEK 2 according to two species. On the other hand, 79 isolates were ESBL producers by TZ/TZL, 83 isolates were ESBL producers by CT/CTL and 80 isolates were ESBL producers by DDST according to five species.

---

### Table 2. The antibiotic activity (%) on the multi-resistant isolates.

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Antibiotic</th>
<th>MEM</th>
<th>TGC</th>
<th>AK</th>
<th>NI</th>
<th>GM</th>
<th>PTZ</th>
<th>AUG</th>
<th>CIP</th>
<th>TS</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> (n = 54)</td>
<td></td>
<td>100</td>
<td>98</td>
<td>96</td>
<td>72</td>
<td>63</td>
<td>89</td>
<td>39</td>
<td>18.5</td>
<td>20.3</td>
</tr>
<tr>
<td><em>K. pneumoniae</em> (n = 18)</td>
<td></td>
<td>100</td>
<td>100</td>
<td>66.6</td>
<td>16.5</td>
<td>22</td>
<td>83</td>
<td>5.5</td>
<td>28</td>
<td>11.1</td>
</tr>
<tr>
<td><em>P. aeruginosa</em> (n = 11)</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><em>Pr. mirabilis</em> (n = 6)</td>
<td></td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>66.6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><em>A. baumannii</em> (n = 4)</td>
<td></td>
<td>50</td>
<td>25</td>
<td>50</td>
<td>50</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>25</td>
<td>50</td>
</tr>
<tr>
<td><em>E. cloacae</em> (n = 5)</td>
<td></td>
<td>100</td>
<td>100</td>
<td>80</td>
<td>0</td>
<td>80</td>
<td>40</td>
<td>0</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td><em>E. aerogenes</em> (n = 1)</td>
<td></td>
<td>100</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong> (n = 99)</td>
<td></td>
<td>86.8</td>
<td>84.8</td>
<td>77.7</td>
<td>42.4</td>
<td>43.4</td>
<td>71.7</td>
<td>22.2</td>
<td>21.2</td>
<td>18.2</td>
</tr>
</tbody>
</table>

AUG, Amoxicillin / clavulanic acid; CIP, ciprofloxacin; TS, Trimethoprime / sulfamethoxazole; MEM, meropenam; PTZ, tazocin; NI, nitrofurantoin; AK, amikacin; GM, gentamicin; TGC, tigecycline; *n*, number of isolates.

### Table 3. The phenotypic and molecular characterizations of the isolated ESBL producing gram negative bacteria.

<table>
<thead>
<tr>
<th>Organism</th>
<th>VITEK</th>
<th>D.D.S.T.</th>
<th>E-test</th>
<th>PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AMC/CAZ/CTX</td>
<td>TZ/TZL</td>
<td>CT/CTL</td>
</tr>
<tr>
<td><em>E. coli</em> (n = 54)</td>
<td>53</td>
<td>53</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td><em>K. pneumoniae</em> (n = 18)</td>
<td>18</td>
<td>18</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td><em>E. cloacae</em> (n = 5)</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td><em>E. aerogenes</em> (n = 1)</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>P. mirabilis</em> (n = 6)</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td><strong>Total</strong> (n = 84)</td>
<td>71</td>
<td>80</td>
<td>79</td>
<td>83</td>
</tr>
<tr>
<td><strong>Total (%)</strong></td>
<td>84.5</td>
<td>95</td>
<td>94</td>
<td>98.8</td>
</tr>
</tbody>
</table>

The production of ESBL was not detected by one isolate of *E. coli* and four isolates of *E. cloacae*. With cefotaxime ESBL strips (CT/CTL), ESBL activity was detected by all the tested isolates (84%) represented by 100% in *K. pneumoniae*, *P. mirabilis*, *E. aerogenes*, *E. cloacae* and 98% in *E. coli*. The production of ESBL by ceftazidime ESBL strips was not detected in one isolate of *E. coli*. The production of ESBL was not recorded by all the tested *P. aeruginosa* and *A. baumanii* isolates in this study.
Genotypic detection of ESBLs

The PCR products that were amplified by specific primers of ESBL were detected in 75 isolates out of 84 tested ESBL producing gram negative bacteria with 89.3%. The blaTEM genotypes (858 bp) were detected in 40 isolates with 47.6% (Table 3). They were recorded in 20 isolates of E. coli with 37%, 15 isolates of K. pneumoniae with 83.3%, 3 isolates of P. mirabilis with 50%, one isolate of E. cloacae with 20% and one isolate of E. aerogenes with 100%. The blaCTX-M primers detected 499 bp amplicon in 53 isolates with 63.1% of the 84 tested isolates. The blaCTX-M genotypes were reported in 42 isolates of E. coli (78%), 9 isolates of K. pneumoniae with 50%, one isolate of P. mirabilis with 17% and one isolate of E. aerogenes with 100%. All the isolates of E. cloacae did not detect the blaCTX-M gene. The blaSHV primers detected the characteristic of 827 bp amplicon in 51 isolates out of the 84 tested bacteria by 60.7%. The blaSHV genotypes were detected in 37 isolates of E. coli with 68.5%, 12 isolates of K. pneumoniae with 66.6%, one isolate of P. mirabilis with 17% and one isolate of E. aerogenes with 100%. They were not detected in all isolates of E. cloacae. Overall, the blaCTX-M was the commonest genotype (63.1%) followed by blaSHV (60.7%) and blaTEM (47.6%). The most predominant ESBL producer was E. coli (62%) followed by K. pneumoniae (20.2%). The blaSHV, blaTEM and blaCTX-M genotypes in combination were present in 18 isolates with 21.4%. They were detected in K. pneumoniae (6 isolates), E. coli (11 isolates) and one isolate of E. aerogenes. On the other hand, eight isolates out of the 84 bacteria confirmed the presence of plasmid mediated. The gene bank accession numbers of the forward and reverse ESBL producing E. coli (No. 22), respectively. BankIt1534372 JX17252 and BankIt1534380 JX17253 were the gene bank accession numbers for the forward and reverse ESBL producing K. pneumoniae (No. 93), respectively. BankIt1534608 JX17254 and BankIt1534614 JX17255 were the gene bank accession numbers of the forward and reverse ESBL producing E. cloacae (No. 21), respectively.

Conjugation assay

Based on the conjugation assay in this experiment between the recipient cell (E. coli HB101) and the donor cell (E. coli No. 22), the blaCTX-M gene was able to be transferred to transconjugant successfully suggesting that they were plasmid mediated. The gene bank numbers of the resulting DNA sequences of the forward and reverse CTX primers for the transconjugant were identified as bla-CTX-M producing E. coli genes bank No. FJ668785 (99%) similar to the forward and reverse DNA nucleotide sequences of the bla-CTX-M producing E. coli (No. 22).

DISCUSSION

Eighty four (84) out of 560 isolates are ESBL producing gram negative bacteria including E. coli, K. pneumoniae, P. mirabilis, E. cloacae and E. aerogenes. The specimens were collected from different departments while urine samples were from elderly females patients above 50 years old having urinary tract infections. The ESBL infection rate in the hospitalized patients (62%) is higher than the out-patients mainly in the intensive care unit. These results are correlated with that obtained by
Figure 1. The antibiotic activity of the selected multi-resistant isolates. Plates 1 and 2, *E. cloacae* (No. 21); 3 and 4, *E. coli* (No. 22); 5 and 6, *P. mirabilis* (No. 54); 7 and 8, *K. pneumoniae* (No. 93).

Kiratisin et al. (2008) where a total of 2,777 patients were identified as having infections due to *E. coli* or *K. pneumoniae* at both major tertiary-care centers. The majority of patients were over 60 years old and most of...
them had been hospitalized in the intensive care units. All
the ESBL producers were recovered from urine speci-
mens and female patients were the predominant for
particularly ESBL producing *E. coli* infection. Our results
are in agreement with those of Dechen et al. (2009) who
identified 81 ESBL producing isolates out of 238 Gram's
negative bacilli by DDST and phenotypic confirmatory
test. The isolates were *E. coli* (*n* = 34), *K. pneumoniae* (*n*
= 20), *P. aeruginosa* (*n* = 15), *P. mirabilis* (*n* = 3),
*Morganella morganii* (*n* = 5) and *Citrobacter freundii* (*n* =
4). The isolates were collected from 152 urine, 70 wound,
12 blood, 22 sputum and 2 cerebrospinal fluid samples. It
was concluded that ESBL producers can be detected by
DDST and phenotypic confirmatory test with equal
efficacy. Data has shown that VITEK 2 GNI-GNB system
reported all the members of the tested gram negative
bacilli successfully. *E. coli* were the predominant gram's
negative bacilli among the others and MEM was the only
susceptible antibiotic against all the multi-resistant gram
negative isolates.

Caroline and Michael (2003) demonstrated that the
VITEK 2 instrument has an accuracy of 93.0% for the
identification of gram's negative bacilli. Khalid et al.
(2009) reported that out of a total of 11,886 isolated gram
negative bacilli, 2695 were ESBL producers. *E. coli* and
*K. pneumoniae* were the predominant comparatively in
the hospital wards while *Proteus* spp. was predominant in
medical wards. Urine was the major source with low
occurrence in blood cultures. Shah and Mulla (2012)
found that MEM and ETP were effective against ESBL
producers especially *E. coli* and *K. pneumoniae* and
remain good choices for the treatment of suspected
Figure 3. The phenotypic determination of the selected ESBL isolates by E-test strips (CT/CTL Plate 1, *E. cloacae* (No. 21); 2, *E. coli* (No. 22); 3, *P. mirabilis* (No. 54); 4, *K. pneumoniae* (No. 93); 5, *E. coli* ATCC No. 25922.

Figure 4. The phenotypic determination of the selected ESBL isolates by E-test strips (TZ/TZL). Plate 1, *E. cloacae* (No. 21); 2, *E. coli* (No. 22); 3, *P. mirabilis* (No. 54); 4, *K. pneumoniae* (No. 93); 5, *E. coli* ATCC No. 25922.
Figure 5. The agarose gel electrophoresis showing the identical band patterns of the blaTEM (858 bp) and blaSHV (827 bp) produced by *E. cloaca* (No. 21), *E. coli* (No. 22), *P. mirabilis* (No. 54) and *K. pneumonia* (No. 93). Negative band of blaSHV is seen by *E. cloaca* (No. 21).

Figure 6. The agarose gel electrophoresis showing the identical band patterns of the blaCTX-M (499 bp) produced by *E. coli* (No. 22) and *K. pneumoniae* (No. 93). Negative bands of blaCTX-M are detected by *E. cloaca* (No. 21) and *P. mirabilis* (No. 54).
ESBL infections. In the present study, the detection of ESBLs varies between VITEK 2 (84.5%), TZ/TZL (94%), CT/CTL (98.8%) and DDST (95%) on 560 isolates of E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, E. cloacae, E. aerogenes and A. baumannii. The performance characteristics of the conventional methods for the detection of ESBLs (E-test and DDST) were better than the automated system (VITEK2). This finding is in agreement with those of Irith et al. (2007) who compared commercially microbiological identification testing system (VITEK 2) with the conventional phenotypic confirmatory tests (E-test and DDST) to detect ESBL production in gram's negative bacteria. The E-test showed the highest specificity for the detection of ESBLs followed by DDST and VITEK2. They recommended the use of a manual test for confirmation once an organism is reported positive for ESBL production by any of the semi-automated system. Our results also agree with those of Maria et al. (2011) who evaluated the accuracy of positive ESBL results by VITEK 2 regarding clinical isolates of E. coli and K. pneumoniae using DDST and E-test displaying distinct results by which the VITEK 2 system was in disagreement in 23.9% of cases with DDST and in 15.3% with E-test.

Molecular detection in the present work showed that the tested isolates are positive ESBL produced by blaSHV, blaCTX-M and blaTEM genotypes. The bla-CTX-M is the most predominant ESBL gene (63.1%) followed by blaSHV (60.7%) detected in E. coli (62%) and K. pneumoniae (20.2%). Two or more genotypes of ESBL were present in 34 isolates of E. coli, blaCTX-M and blaSHV being the most common combination genes (33.3%) followed by bla-SHV with bla-TEM and bla-CTX-M (11%). ESBL were present in 17 isolates of K. pneumoniae, bla-SHV and bla-TEM being the most combination genes (39%) followed by blaSHV with blaTEM and blaCTX-M (28%). This finding is in agreement with those of Ankur et al. (2009) who examined ESBL production phenotypically for a total of 200 consecutive clinical isolates of E. coli (n = 143) and K. pneumoniae (n = 57) collected at a tertiary care hospital followed by further typed for the blaTEM / SHV / CTX-M genes by PCR using specific primers. ESBLs were found in 63.6% of E. coli isolates and 66.7% of K. pneumoniae isolates and majority of them harboured two or more ESBL genes (57.3%). Overall, blaCTX-M was the commonest genotype (85.4%) followed by blaTEM (54.9%) and blaSHV (32.9%) either alone or in combination. Two or more genes for ESBL were present in 47 out of 82 ESBL isolates including the blaTEM with blaCTX-M being the most common combination (28.1%). They concluded high ESBL occurrence with CTX-M as the emerging type in the selected hospital. The results in the present study identified successfully the selected ESBL producing gram negative bacteria by 16SrDNA. Identification of bacteria by 16S rDNA gene sequences analysis in the present work discriminate more finely among the selected strains than is possible with phenotypic methods. Thus, it provides an accurate identification at the species level and can clarify the clinical importance of the isolated bacteria of the infectious diseases (Fredricks and Relman, 1996; Clarridge et al., 2001).

Tang et al. (2000) compared a variety of identification systems including cellular fatty acid profiles, carbon source utilization and conventional biochemical identification with the 16SrRNA gene sequence to evaluate both unusual aerobic gram negative bacilli isolated from clinical specimens. They found that 16SrRNA gene sequence provided more rapid, unambi-
gous identification of the difficult bacterial isolates than did conventional methods and that this identification could translate to improve clinical outcomes.

Bosshard et al. (2003) found that only a minority of the clinical laboratory isolates of aerobic gram negative rods could be correctly identified by phenotypic methods whereas 16SrRNA gene sequencing is an excellent method for identifying these organisms which are difficult to identify by conventional methods. Our results show that the blaCTX-M genotype of *E. coli* (No. 22) is able to be transferred to transconjugant successfully when conjugated with *E. coli* (HB101); this suggests that they are plasmid mediated.

Iroha et al. (2010) reported that ESBLs are carried on bacterial chromosomes or plasmids and plasmid-mediated ESBLs can carry genes on them that have the ability to transfer a replica of themselves to other bacteria. They also can carry genes conferring resistance to other classes of antibiotics that make the recipient bacteria resistant to multiple antibiotics. Furthermore, these plasmids can emerge on strains that do not cause human diseases and then the non-pathogenic strains could transfer their plasmids to strains that can cause human diseases.

Plasmid conjugation is an important mechanism of disseminating drug resistance among bacteria population. In conclusion, the prevalence rate of ESBL producing organisms is high globally. The ESBL producing organisms are known to cause serious nosocomial infections, long term carriage in the community, community-acquired infections such as urinary tract infections and intra-abdominal abscess. The findings from the present study reveal high prevalence of ESBL from Ahmadi hospital in Kuwait where *E. coli* is the highest producer followed by *K. pneumoniae*, *P. mirabilis*, *E. cloacae* and *E. aerogenes*, respectively. ESBL producers can be detected by E-test and DDST with equal efficacy. The blaCTX-M is the most predominant ESBL genotypes among the multiresistant gram negative bacteria including the third generation of cephalosporins. Thus, this study emphasizes the inclusion of ESBL detection in routine laboratory tests in hospitals and clinics especially in the developing countries.

ACKNOWLEDGEMENT

The authors wish to thank Professor Dr. Ali A. Dashti, Professor of Microbiology, Medical Laboratory Science Department, Faculty of Allied Health Science, Health Science Center, Kuwait University, Kuwait, for his excellent technical assistance.

REFERENCES


